Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

Executive Summary

The National Organization for Rare Disorders’ campaign to get FDA to codify a flexible approach on approving orphan drugs is now bolstered by an analysis that concludes most of the agency’s approval decisions for such products already use unconventional efficacy standards.

You may also be interested in...



US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says

Attorney Frank Sasinowski says the agency should include new "boilerplate language" in official documents describing scientific flexibility for orphan drug approval requirements.

US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.

US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.

Related Content

Topics

UsernamePublicRestriction

Register

PS053857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel